Grogan Health Affairs CED Article with GPT4 "SUMMARY"

While ChatGPT has no data after 2021, it can summarize new content by the "instrucdtion plus cut paste" method.  The input has a limit of about 2000 words.*

This is the GROGAN 2000 word article on CED cut pasted into Chat GPT4 with the word "SUMMARIZE".

The Coverage with Evidence Development (CED) program introduced by the Centers for Medicare and Medicaid Services (CMS) during the George W. Bush administration to increase access to new medical technologies through agency-approved clinical trials has created barriers to patient access and hampered innovation. Despite this, CMS has been applying this policy to drugs, including a new class of Alzheimer’s treatments, which is not appropriate. The drawbacks associated with CED are pervasive, and CMS should abandon the program or at least restrict its use only for off-label applications of therapies.

This is the same GROGAN 2000 word article cut pasted into Chast with the instruction, "SUMMARIZE FOR AN EXPERT.  YOU ARE ALSO AN EXPERT."

The Centers for Medicare and Medicaid Services (CMS) introduced "Coverage with Evidence Development" (CED) to increase access to innovative medical devices through agency-approved clinical trials. However, CED has become a barrier to patient access and innovation. The program has been applied to therapies on-label for the first time, allowing CMS to act as a "check" on the FDA. This has hampered innovation, with examples including slow coverage for CAR-T cell therapy and continuous glucose monitors, and the repeal of the Medicare Coverage of Innovative Technologies rule.

Since 2005, 27 medical devices or procedures have been subjected to CED, but only four have completed evidence development programs and retained national coverage. CED creates a never-ending coverage purgatory for innovators, requiring significant resources and time to navigate. Applying CED to drugs is even less appropriate due to the extensive research process they undergo with the FDA, rendering CMS's attempts at safety monitoring redundant.

CMS should abandon CED or reform and restrict its use only for off-label applications of therapies. The agency should prioritize reforming or eliminating CED to ensure Medicare patients have access to innovations they need. 

Finally, this is a free Chrome Plug In called "Chat GPT > Summarize Everything."  At the webpage of interest, you tap this Chrome plug in button and it generates both a short summary and it adds key bullet points.  The result:

Summary

The Coverage with Evidence Development (CED) program introduced by the Centers for Medicare and Medicaid Services (CMS) during the George W. Bush administration to increase access to new medical technologies through agency-approved clinical trials has created barriers to patient access and hampered innovation. Despite this, CMS has been applying this policy to drugs, including a new class of Alzheimer’s treatments, which is not appropriate. The drawbacks associated with CED are pervasive, and CMS should abandon the program or at least restrict its use only for off-label applications of therapies.

Facts

• CED is a never-ending coverage purgatory for innovators, with more than 30 complex steps required to establish a program. The resources required to facilitate CED can inhibit evidence development.
• CED creates inconsistencies in coverage rules and access based on where a Medicare beneficiary lives, as contractors can set different rules for the regions they cover.
• CED should not be used for any FDA-approved product, especially drugs, given the stricter approval requirements drugs face from the FDA.
• CMS has been reaching for CED more often with respect to drugs, which is inappropriate.
• CMS has pledged to cover a new class of Alzheimer’s drugs only under the burdens associated with CED, severely curtailing patient benefit. Numerous stakeholders have pointed out the flaws with this approach.
• To address these concerns, CMS should scrap CED altogether, choosing instead to default to coverage of on-label use for FDA-approved drugs.
• CMS should prioritize reforming or eliminating CED and allow Medicare patients to finally have access to the innovations they are counting on to enjoy their golden years.

In its toolbox, the plug-in uses this default script:

Your output should use the following template:

### Summary

### Facts

- [Emoji] Bulletpoint

Your task is to summarize the text I give you in up to seven bulletpoints and start with a short summary.

##

* You can use input > 2000 words by workarounds like, "Read this section and reply "READ." Don't do anything else.  / PART ONE [2000 words]."   Repeast with PART TWO [2000 words] etc.  When the parts are cut pasted 2000 words at a time in series, now a new instruction, "Please summarize parts 1 to 4 above."